0 NASDAQ Companies - October 21, 2024Li Auto Inc. to Report Third Quarter 2024 Financial Results on October 31, 2024BEIJING, China, Oct. 21, 2024 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), […]Read More
0 NASDAQ Companies - October 21, 2024Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program CommitteesPhase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentum DIAMOND program […]Read More
0 NASDAQ Companies - October 21, 2024Niu Technologies to Report Third Quarter 2024 Financial Results on November 18, 2024BEIJING, Oct. 21, 2024 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of […]Read More
0 NASDAQ Companies - October 21, 2024InterDigital and The University of Texas at Austin to Showcase Over-the-Air Federated Learning for AI Model Training at Brooklyn 6G SummitWILMINGTON, Del., Oct. 21, 2024 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and […]Read More
0 NASDAQ Companies - October 21, 2024Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateLONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) […]Read More
0 NASDAQ Companies - October 21, 2024Nasdaq Confirms VEON’s Full Compliance Following its 2023 20-F FilingAmsterdam and Dubai, 21 October 2024: VEON Ltd. (Nasdaq: VEON; Euronext Amsterdam: VEON), a global digital operator (“VEON” or the […]Read More
0 NYSE Companies - October 18, 2024NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing […]Read More
0 NASDAQ Companies - October 18, 2024Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming DaysWARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a […]Read More